

RESEARCH ARTICLE

The role of area-level socioeconomic disadvantage in racial disparities in cancer incidence in metropolitan Detroit

Kristen S. Purrington^{1,2}  | Theresa A. Hastert^{1,2}  | K. C. Madhav³ | Mrudula Nair¹ | Natalie Snider¹ | Julie J. Ruterbusch^{1,2} | Ann G. Schwartz^{1,2} | Elena M. Stoffel⁴ | Edward S. Peters⁵ | Laura S. Rozek⁶

¹Department of Oncology, Wayne State University School of Medicine, Michigan, Detroit, USA

²Population Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Michigan, Detroit, USA

³Department of Internal Medicine, Yale School of Medicine, Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Connecticut, New Haven, USA

⁴Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Michigan, Ann Arbor, USA

⁵Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA

⁶Department of Oncology, Georgetown University School of Medicine, District of Columbia, Washington, USA

Correspondence

Kristen S. Purrington, Department of Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, 4100 John R, Mailcode: MM04EP, Detroit, MI 48201, USA.
Email: purringk@karmanos.org

Funding information

Foundation for the National Institutes of Health, Grant/Award Number: HHSN261201300011I and P30CA022453; National Cancer Institute, Grant/Award Number: R01CA259420

Abstract

Background: Neighborhood deprivation is associated with both race and cancer incidence, but there is a need to better understand the effect of structural inequities on racial cancer disparities. The goal of this analysis was to evaluate the relationship between a comprehensive measure of neighborhood-level social disadvantage and cancer incidence within the racially diverse population of metropolitan Detroit.

Methods: We estimated breast, colorectal, lung, and prostate cancer incidence rates using Metropolitan Detroit Cancer Surveillance System and US decennial census data. Neighborhood socioeconomic disadvantage was measured by the Area Deprivation Index (ADI) using Census Bureau's American Community Survey data at the Public Use Microdata Areas (PUMA) level. Associations between ADI at time of diagnosis and cancer incidence were estimated using Poisson mixed-effects models adjusting for age and sex. Attenuation of race-incidence associations by ADI was quantified using the “mediation” package in R.

Results: ADI was inversely associated with incidence of breast cancer for both non-Hispanic White (NHW) and non-Hispanic Black (NHB) women (NHW: per-quartile RR=0.92, 95% CI 0.88–0.96; NHB: per-quartile RR=0.94, 95% CI 0.91–0.98) and with prostate cancer incidence only for NHW men (per-quartile RR=0.94, 95% CI 0.90–0.97). ADI was positively associated with incidence of lung cancer for NHWs and NHBs (NHW: per-quartile RR=1.12, 95% CI 1.04–1.21; NHB: per-quartile RR=1.37, 95% CI 1.25–1.51) and incidence of colorectal cancer (CRC) only among NHBs (per-quartile RR=1.11, 95% CI 1.02–1.21). ADI significantly attenuated the relationship between race and hormone receptor positive, HER2-negative breast cancer (proportion attenuated=8.5%, 95% CI 4.1–16.6%) and CRC cancer (proportion attenuated=7.3%, 95% CI 3.7 to 12.8%), and there was a significant interaction between race and ADI for lung (interaction RR=1.22, $p < 0.0001$) and prostate cancer (interaction RR=1.09, $p = 0.00092$).

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Cancer Medicine* published by John Wiley & Sons Ltd.

Conclusions: Area-level socioeconomic disadvantage is associated with risk of common cancers in a racially diverse population and plays a role in racial differences in cancer incidence.

KEYWORDS

geography, racial disparities, social disadvantage, socioeconomic status

1 | INTRODUCTION

Breast, prostate, colorectal, and lung cancers are estimated to account for nearly half of all cancers diagnosed in the United States in 2022 and nearly half of all cancer deaths. While overall incidence of these cancers has declined in the last decade, racial disparities persist. In particular, non-Hispanic Blacks (NHB) are at increased risk of prostate, colorectal, lung, and certain aggressive breast cancers, and are more likely to be diagnosed at younger ages compared to non-Hispanic Whites (NHW).¹ Race is a social construct and, as such, racial disparities in cancer incidence stem from a complex interplay between biological, environmental, social, behavioral, and structural risk factors.²⁻⁴ Work from initiatives such as the Public Health Disparities Geocoding Project has substantially advanced our understanding of how policies such as redlining and mortgage discrimination affect the health of minority populations by creating segregated neighborhoods with adverse socioeconomic status, fewer educational and economic opportunities, increased exposures linked to cancer, and reduced access to high-quality healthcare.⁵⁻¹¹ Despite these advances, there is a clear need for further research to better understand the effect of these structural inequities on racial cancer disparities.^{4,11}

The social and built environment have been shown to be as important as individual characteristics for the development of complex health conditions, including cancer.⁵⁻¹⁰ NHBs on average have lower socioeconomic status (SES) compared to NHWs, and NHBs with low SES are at higher risk of cancer and poorer cancer outcomes.¹²⁻¹⁴ Higher individual-level SES is associated with increased breast and prostate cancer incidence^{15,16} and lower colorectal and lung cancer incidence.^{17,18} However, individual-level measures do not capture potentially relevant neighborhood factors such as the physical environment and neighborhood resources.^{19,20} A study of the relative contributions of area-level and individual-level SES measures using the VITamins And Lifestyle (VITAL) cohort found that the significant effects of area-level SES on cancer incidence were only partially explained by individual-level education and income, indicating that these neighborhood factors confer risk independent of individual-level SES.²¹ Studies of neighborhood SES and

other neighborhood characteristics have not only demonstrated that these factors are associated with cancer incidence, but that individual-level SES may differentially affect different racial/ethnic groups within different contexts of neighborhood racial composition, residential mobility, and population density.²²

The goal of the analyses presented in this manuscript was to evaluate the relationship between a comprehensive measure of neighborhood-level social disadvantage and cancer incidence within the racially diverse population of metropolitan Detroit. We utilized Singh's Area Deprivation Index (ADI), a validated deprivation index that has been associated with poor health outcomes both in the United States and globally,²³⁻²⁵ but its utility in understanding racial differences in cancer incidence was previously unknown. Specifically, we hypothesized that (1) higher disadvantage would be associated with higher cancer incidence rates and (2) because ADI captures many of the adverse conditions that lead to increased cancer incidence among African Americans, ADI would partially attenuate known relationships between race and cancer incidence. Here we present the results of an analysis linking Singh's ADI with incident cancer data from the Metropolitan Detroit Cancer Surveillance System (MDCSS), a population-based cancer registry in Wayne, Oakland, and Macomb counties in Michigan to determine whether area-level deprivation is associated with cancer incidence.

2 | METHODS

2.1 | Identification of cancers in metropolitan Detroit (numerator)

All incident primary invasive female breast, prostate, lung, and colorectal cancers among NHW or NHB diagnosed in Wayne, Oakland, and Macomb counties in Michigan between 2012 and 2016 ($n=42,348$) were identified in MDCSS. Excluding individuals diagnosed under 18 years of age, our final sample consisted of 42,332 individuals (12,105 female breast, 6976 colorectal, 11,084 lung, and 12,167 prostate cancers). Molecular subtype was available for breast cancer cases, including 7920 hormone receptor positive (HR+)/HER2-negative (HER2-) cases, 1370

HR+/HER2-positive (HER2+) cases, 581 hormone receptor negative (HR-)/HER2+ cases, 1515 HR-/HER2- cases, and 719 cases with unknown subtype (Table 1). This study was conducted under a protocol given concurrence of exemption by the Wayne State University Institutional Review Board on April 23, 2002.

2.2 | Metropolitan Detroit population count data by geographic region (denominator)

We obtained population counts for each of the 27 Public Use Microdata Areas (PUMAs) contained entirely within Wayne, Oakland, and Macomb counties in Michigan stratified by age (by year of age for individuals 18+ years old), race (African American, white), and sex (male, female) from United States 2010 decennial census Integrated Public-Use Microdata Samples (IPUMS) (<https://usa.ipums.org/usa/>). PUMAs are geographic units used by the United States Census for providing statistical and demographic information, containing at least 100,000 people, and these units represent the smallest geographic units for which population count data are available stratified by race, age, and sex.

2.3 | Geocoding residential addresses for cancer cases

Residential addresses for MDCSS-identified cases at the time of cancer diagnosis were geocoded using the Federal Information Processing Standard (FIPS) convention to identify census tract for each cancer case. To achieve comparability in geographic region for cancer cases and population counts, we then identified the census tracts contained within each metropolitan Detroit PUMA unit using the “2010 Census Tract to 2010 PUMA Relationship File” (<https://census.gov/program-surveys/geography/guidance/geo-areas/pumas.html>).

2.4 | Area-level deprivation index calculation

We calculated ADI at the census-tract level for each of 1166 census tracts in Wayne, Oakland, and Macomb counties in Michigan. Census tract geocodes were obtained from GIS Open Data (2010 Census Tracts v17a, <https://gis-michigan.opendata.arcgis.com/datasets/>). Michigan's 5-year estimates (2009–2013) from the Census Bureau's American Community Survey (ACS) were abstracted from the US census. The census-derived indicators used

in the calculation of ADI include educational distribution (percentage of the population with less than 9 years and with 12 or more years of education), median family income, median home value, median gross rent, median monthly mortgage, income disparity, unemployment, percent employed person in white-collar occupation, percent families below poverty, percent population below 150% poverty threshold, single-parent household rate, homeownership rate, percent household without a telephone, percent household without a motor vehicle, percent occupied housing units without complete plumbing, and household crowding. The 17 US census indicators were multiplied by the Singh's coefficients (factor weights) and summed to obtain the base score for all census tracts in the catchment area.^{26,27} Each base score was standardized by dividing the difference between the individual census tract base score (b) and census tract mean (p), by census tract standard deviation (S_p).

$$\text{Standard base}(j) = \frac{b - p}{S_p} \quad j = 1, 2, \dots, k$$

where j represents the j th census tract and k is the total number of census tracts in the catchment area. Standardized values were adjusted to a base mean of 100 and a standard deviation of 20²⁶:

$$\text{ADI}_j = (\text{Standard base}_j + 100) * 20$$

Higher ADI scores correspond to higher socioeconomic disadvantage. To map census tract-level ADI scores to PUMAs, we calculated the weighted median of census-tract ADI scores within each PUMA, with weights corresponding to the population size of each census tract. PUMA-level weighted median scores were then linked to the MDCSS-identified cancer cases and population-level count data.

2.5 | Statistical analyses

All statistical analyses were conducted in R (<https://cran.r-project.org/>). To aid with interpretability, weighted median ADI was categorized into quartiles, where quartile boundaries were calculated using the overall study population ADI distribution across all metropolitan Detroit census tracts. Univariable associations between demographics, race, and ADI were examined using chi-squared tests and Wilcoxon rank sum tests for categorical and continuous variables, respectively. Age- and sex-adjusted incidence rates were calculated using the “rate” function in the “popEpi” R package, where person-years (PY) were calculated as $\text{population size}_{\text{age-sex stratum}} \times 5 \text{ years}$ and weights were calculated as the sum of the total PY per age-sex stratum.

TABLE 1 Demographic characteristics of cancer cases and the population of metropolitan Detroit.

	Breast				Colorectal	Lung	Prostate	Population
	HR+/HER2-	HR-/HER2+	HR+/HER2+	HR-/HER2-				
Overall	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Total	12,105	7920	581	1370	1515	6976	11,084	2,686,466
Age ^a								
18-34	224 (1.9)	95 (1.2)	18 (3.1)	52 (3.8)	47 (3.1)	137 (2.0)	22 (0.2)	723,528 (26.9)
35-44	1054 (8.7)	586 (7.4)	64 (11.0)	190 (13.9)	172 (11.4)	301 (4.3)	136 (1.2)	426,680 (15.9)
45-54	2607 (21.5)	1644 (20.8)	150 (25.8)	344 (25.1)	359 (23.7)	1168 (16.7)	995 (9.0)	512,106 (19.1)
55-64	3323 (27.5)	2191 (27.7)	171 (29.4)	383 (28.0)	406 (26.8)	1696 (24.3)	2954 (26.7)	490,685 (18.3)
65-74	2706 (22.4)	1907 (24.1)	107 (18.4)	240 (17.5)	314 (20.7)	1661 (23.8)	3607 (32.5)	298,476 (11.1)
75-84	1537 (12.7)	1111 (14.0)	47 (8.1)	120 (8.8)	149 (9.8)	1261 (18.1)	2492 (22.5)	154,822 (5.8)
85+	654 (5.4)	386 (4.9)	24 (4.1)	41 (3.0)	68 (4.5)	752 (10.8)	878 (7.9)	80,169 (3.0)
Sex								
Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3480 (49.9)	5532 (49.9)	1,274,113 (47.4)
Female	12,105 (100)	7920 (100)	581 (100)	1370 (100)	1515 (100)	3496 (50.1)	5552 (50.1)	1,412,353 (52.6)
Race								
Non-Hispanic White	9089 (75.1)	6232 (78.7)	413 (72.1)	1020 (74.5)	904 (59.7)	5009 (71.8)	8378 (75.6)	1,979,087 (73.7)
Non-Hispanic Black	3016 (24.9)	1688 (21.3)	168 (28.9)	350 (25.5)	611 (40.3)	1967 (28.2)	2706 (24.4)	707,379 (26.3)
ADI quartile								
1	3534 (29.2)	2431 (30.7)	165 (28.4)	378 (27.6)	346 (22.8)	1622 (23.2)	2291 (20.7)	723,361 (26.9)
2	3600 (29.7)	2381 (30.1)	157 (27.0)	421 (30.7)	442 (29.2)	1971 (28.3)	3104 (28.0)	768,044 (28.6)
3	2393 (19.8)	1533 (19.4)	126 (21.7)	286 (20.9)	301 (19.9)	1623 (23.3)	2823 (24.5)	567,826 (21.1)
4	2578 (21.3)	1575 (19.9)	133 (22.9)	285 (20.8)	426 (28.1)	1760 (25.2)	2866 (25.9)	627,235 (23.3)

^aAge at diagnosis for cancer cases, age at census for general population.

Incidence rates were calculated separately for breast cancer, colorectal cancer, prostate cancer, and lung cancer, stratified by race (NHW and NHB). Risk ratios were calculated using a Poisson mixed-effects model to account for group-level PUMA effects as implemented by the “glmer” function in the “lme4” R package adjusting for age and sex, as appropriate. ADI quartile was operationalized as a categorical variable for the majority of analyses, using ADI quartile 1 as the reference (Tables 2 and 3). Associations with a significant p_{trend} are summarized in the results section for simplicity using ADI as an ordinal variable. We used the “mediation” package to quantify the proportion of the total association of race on cancer incidence attenuated by inclusion of ADI in our multivariable models. Post hoc analysis evaluating ADI as an effect modifier of the relationship between race and cancer incidence was conducted by including a race \times ADI interaction term in these models. Maps were generated using GeoDa software.²⁸

3 | RESULTS

Cancer incidence rates across the 27 PUMA units in metropolitan Detroit ranged from 4.6 to 1222.6 cases per 100,000 PY across the four cancer sites (Figure 1). Median PUMA-level cancer incidence was higher among NHBs compared to NHWs for breast (209.1 vs. 174.0 per 100,000 PY, $p=0.018$), colorectal (70.5 vs. 52.3 per 100,000 PY, $p=0.0033$), and prostate cancer (327.9 vs. 179.2 per 100,000 PY, $p=0.00015$). Incidence rates were also more variable for NHB than for NHWs across all cancer sites, where the interquartile ranges (IQR) of PUMA-level incidence rates were 2.5- to 4.5-fold higher for NHBs compared to NHWs (Breast IQR: 72.1 vs. 28.6 per 100,000 PY; Colorectal IQR: 23.6 vs. 12.4 per 100,000 PY; Lung IQR: 88.2 vs. 37.1 per 100,000 PY; Prostate IQR: 146.4 vs. 32.3 per 100,000 PY, for NHB vs. NHW, respectively).

The majority of cases were diagnosed between 45 and 85 years of age, where women with breast cancer had a lower median age at diagnosis (61 years) and individuals with lung cancer had higher median age at diagnosis (68 years) than individuals with colorectal and prostate cancers (65 years) ($p<0.0001$) (Table 1). Colorectal and lung cancer cases were approximately evenly distributed among men and women. The majority of cases were non-Hispanic White (NHW, ~73%), except for triple negative (TN) breast cancer, which had a substantially higher proportion of NHB women (40.3%). The majority of cancer cases lived in areas assigned to ADI quartiles 1 and 2 (Tables 1). At the PUMA unit-level, the proportion of residents of self-reported NHB race was highly correlated with ADI quartile (Spearman $\rho=0.79$, $p<0.0001$; Global Moran's $I=0.46$) (Figure S1). The distribution of the 17 US

census factors used to calculate ADI are shown by ADI quartile in Table S1.

ADI was inversely associated with overall breast cancer incidence among NHW and NHB women adjusting for age (NHW: per-quartile RR = 0.92, 95% CI 0.88–0.96, $p=0.00028$; NHB: per-quartile RR = 0.94, 95% CI 0.91–0.98, $p=0.0017$) (Table 2). This inverse association remained only for HR+/HER2– breast cancer incidence among NHW women (per-quartile RR = 0.92, 95% CI 0.87–0.96, $p=0.00079$), HR+/HER2+ (per-quartile RR = 0.89, 95% CI 0.80–0.98, $p=0.024$), TN (per-quartile RR = 0.90, 95% CI 0.82–0.97, $p=0.010$), and marginally for HR+/HER2– (per-quartile RR = 0.93, 95% CI 0.88–1.01, $p=0.056$) breast cancer incidence among NHB women. ADI was also inversely associated with prostate cancer incidence among NHW men (per-quartile RR = 0.94, 95% CI 0.90–0.97, $p=0.00053$), but was not significantly associated with prostate cancer incidence among NHB men. Interestingly, while not statistically significant, ADI was associated with an increased risk of prostate cancer among NHB men (per-quartile RR = 1.06, 95% CI 0.97–1.15). ADI was also significantly associated with increased colorectal and lung cancer incidence among both NHW and NHB individuals, adjusting for age and sex. Among NHWs, colorectal cancer risk was significantly increased only among ADI quartiles 2 and 3 compared to quartile 1. Among NHBs, each increase in ADI quartile was associated with an 11% increase in colorectal cancer risk (95% CI 1.02–1.21, $p=0.010$). Among NHWs, lung cancer incidence increased 12% for each increase in ADI quartile (95% CI 1.04–1.21, $p=0.0028$). ADI was more strongly associated with lung cancer incidence among NHBs where each increase in ADI quartile was associated with a 37% increase in risk (95% CI 1.25–1.51, $p<0.0001$).

We next evaluated the relationship between race and cancer incidence as a first step toward evaluating the role of ADI in this relationship (Table 3). We observed significantly higher cancer incidence rates among NHBs compared to NHWs for TN breast, colorectal, prostate, and lung cancers. NHBs were 11% more likely to be diagnosed with lung cancer (95% CI 1.07–1.16, $p<0.0001$), 33% more likely to be diagnosed with colorectal cancer (95% CI 1.26–1.40, $p<0.0001$), 64% more likely to be diagnosed with prostate cancer (95% CI 1.58–1.71, $p<0.0001$), and nearly twofold more likely to be diagnosed with TN breast cancer (95% CI 1.76, 2.17, $p<0.0001$) than NHWs controlling for age and sex, when appropriate. NHB women were about 20% less likely to be diagnosed with HR+/HER2– breast cancer (95% CI 0.74–0.83, $p<0.0001$).

Hypothesizing that inclusion of ADI would attenuate the relationship between race and cancer incidence in these models, we further adjusted for ADI and evaluated

TABLE 2 Age- and sex-adjusted incidence rate and rate ratios by ADI quartile and cancer site for non-Hispanic Whites and non-Hispanic Blacks.

	Non-Hispanic White		Non-Hispanic Black	
	IR ^a (95% CI)	RR (95% CI), <i>p</i> _{trend}	IR ^a (95% CI)	RR (95% CI), <i>p</i> _{trend}
Breast cancer: overall				
ADI: Q1	177.7 (171.7, 183.9)	1.00 (ref)	189.7 (151.1, 238.3)	1.00 (ref)
ADI: Q2	171.2 (165.1, 177.5)	0.93 (0.83, 1.03)	186.1 (170.5, 203.2)	1.00 (0.85, 1.19)
ADI: Q3	161 (153.9, 168.4)	0.85 (0.76, 0.96)	181.1 (163.3, 200.8)	0.94 (0.79, 1.12)
ADI: Q4	164.6 (153.2, 176.8)	0.78 (0.67, 0.91), 0.00028	159.9 (152.5, 167.6)	0.87 (0.75, 1.02), 0.0017
Breast: HR+, HER2–				
ADI: Q1	124.2 (119.2, 129.4)	1.00 (ref)	110.9 (77.6, 158.4)	1.00 (ref)
ADI: Q2	116.7 (111.7, 121.9)	0.91 (0.80, 1.02)	106.8 (95.0, 120.1)	1.11 (0.88, 1.40)
ADI: Q3	106.5 (100.8, 112.6)	0.81 (0.71, 0.93)	101.5 (88.3, 116.7)	1.00 (0.79, 1.28)
ADI: Q4	117.0 (107.5, 127.4)	0.79 (0.67, 0.94), 0.00079	90.5 (85.0, 96.4)	0.96 (0.77, 1.19), 0.056
Breast: HR–, HER2+				
ADI: Q1	8.4 (7.1, 9.8)	1.00 (ref)	7.2 (3.7, 13.9)	1.00 (ref)
ADI: Q2	7.4 (6.2, 8.8)	0.85 (0.66, 1.10)	9.4 (6.4, 13.8)	1.01 (0.48, 2.16)
ADI: Q3	8.2 (6.7, 10.0)	0.92 (0.70, 1.22)	11.1 (7.3, 16.7)	1.16 (0.54, 2.50)
ADI: Q4	6.9 (4.9, 9.7)	0.80 (0.54, 1.19), 0.32	8.7 (7.1, 10.6)	0.99 (0.49, 1.98), 0.87
Breast: HR+, HER2+				
ADI: Q1	19.0 (17.1, 21.1)	1.00 (ref)	16.6 (10.3, 26.8)	1.00 (ref)
ADI: Q2	19.4 (17.4, 21.6)	0.97 (0.83, 1.14)	25.7 (20.4, 32.3)	1.40 (0.85, 2.30)
ADI: Q3	20.1 (17.7, 22.8)	0.97 (0.82, 1.16)	17.9 (13.1, 24.6)	0.95 (0.55, 1.63)
ADI: Q4	19.7 (16.0, 24.3)	0.93 (0.73, 1.19), 0.60	17.3 (15.0, 19.9)	0.93 (0.58, 1.49), 0.024
Breast: HR–, HER2–				
ADI: Q1	16.0 (14.2, 17.9)	1.00 (ref)	46.7 (34.7, 62.6)	1.00 (ref)
ADI: Q2	18.7 (16.8, 20.9)	1.12 (0.91, 1.38)	35.8 (29.5, 43.5)	0.71 (0.51, 0.99)
ADI: Q3	17.3 (15.1, 19.8)	1.02 (0.82, 1.28)	37.9 (30.4, 47.3)	0.74 (0.53, 1.05)
ADI: Q4	15.4 (12.2, 19.4)	0.88 (0.64, 1.20), 0.54	31.6 (28.4, 35.1)	0.63 (0.47, 0.85), 0.010
Colorectal cancer				
ADI: Q1	41.3 (39.3, 43.5)	1.00 (ref)	48.8 (37.5, 63.4)	1.00 (ref)
ADI: Q2	47.4 (45.2, 49.8)	1.13 (1.03, 1.25)	59.4 (52.6, 67.1)	1.14 (0.85, 1.54)
ADI: Q3	55.3 (52.4, 58.4)	1.32 (1.19, 1.46)	67.1 (58.8, 76.6)	1.31 (0.97, 1.77)
ADI: Q4	45.9 (41.7, 50.4)	1.04 (0.91, 1.19), 0.084	65.9 (62.3, 69.7)	1.39 (1.05, 1.84), 0.010
Lung cancer				
ADI: Q1	60.5 (58.0, 63.1)	1.00 (ref)	33.3 (24.3, 45.5)	1.00 (ref)
ADI: Q2	77.8 (74.9, 80.8)	1.23 (1.04, 1.46)	65.4 (58.2, 73.4)	1.99 (1.45, 2.74)
ADI: Q3	105.3 (101.2, 109.5)	1.67 (1.40, 2.00)	90.4 (80.3, 101.8)	2.58 (1.88, 3.54)
ADI: Q4	91.0 (85.1, 97.3)	1.28 (1.06, 1.55), 0.0028	101.0 (96.5, 105.7)	3.18 (2.36, 4.29), <0.0001
Prostate cancer				
ADI: Q1	172.5 (166.6, 178.7)	1.00 (ref)	277.4 (234.4, 328.4)	1.00 (ref)
ADI: Q2	168.2 (162, 174.6)	0.95 (0.86, 1.04)	289.8 (265.8, 315.9)	1.11 (0.85, 1.45)
ADI: Q3	159 (151.7, 166.7)	0.88 (0.80, 0.98)	278.9 (252.5, 308.1)	1.10 (0.84, 1.45)
ADI: Q4	151.9 (141.1, 163.5)	0.81 (0.72, 0.92), 0.00048	279 (267.8, 290.6)	1.21 (0.95, 1.55), 0.173

^aIncidence rate per 100,000 person-years adjusted for age and sex (lung and colorectal only).

TABLE 3 Associations between race and cancer incidence before and after adjustment for ADI.

	Non-Hispanic White	Non-Hispanic Black	Age- and sex-adjusted		Age-, sex-, and ADI-adjusted	
			IR ^a (95% CI)	IR ^a (95% CI)	Rate ratio (95% CI)	p-value
Breast	169.8 (166.3, 173.3)	165.4 (159.5, 171.6)	0.96 (0.92, 1.00)	0.052	1.03 (0.98, 1.08)	0.31
HR+, HER2-	116.5 (113.7, 119.5)	93.2 (88.8, 98.0)	0.79 (0.74, 0.83)	<0.0001	0.83 (0.78, 0.89)	<0.0001
HR-, HER2+	7.8 (7.1, 8.6)	8.9 (7.1, 7.6)	1.13 (0.94, 1.35)	0.20	1.22 (0.97, 1.51)	0.086
HR+, HER2+	19.3 (18.2, 20.6)	18.6 (16.7, 20.8)	0.94 (0.83, 1.06)	0.34	1.01 (0.87, 1.17)	0.88
HR-, HER2-	17.0 (16.0, 18.2)	33.7 (31.0, 36.5)	1.96 (1.76, 2.17)	<0.0001	2.14 (1.88, 2.42)	<0.0001
Colorectal	46.6 (45.3, 48.0)	62.6 (59.8, 65.5)	1.33 (1.26, 1.40)	<0.0001	1.28 (1.20, 1.36)	<0.0001
Lung	78.3 (76.7, 80.1)	88.3 (84.9, 91.8)	1.11 (1.07, 1.16)	<0.0001	0.94 (0.89, 0.99)	0.024
Prostate	165.1 (161.6, 168.7)	273.3 (264.4, 282.4)	1.64 (1.58, 1.71)	<0.0001	1.72 (1.64, 1.81)	<0.0001

^aIncidence rates adjusted for age and sex (colorectal and lung only) per 100,000 persons per year.




FIGURE 1 Incidence rates per 100,000 person-years adjusted for age and sex (colorectal and lung only) for (A) breast, (B) colorectal, (C) lung, and (D) prostate cancer are shown separately for non-Hispanic Blacks (NHB) and non-Hispanic Whites (NHW) in each of 27 public use microdata areas (PUMAs) in Wayne, Oakland, and Macomb counties in Michigan. PUMAs are shaded according to incidence rate decile as indicated by the scale in each panel, with darker blue indicating lower incidence rates and darker red indicating higher incidence rates. Cancer site-specific deciles were calculated with both racial groups combined. Histograms depicting the distribution of PUMAs across incidence rate deciles are shown separately for NHWs and NHBs above the corresponding map.

changes in the relative risks describing the association between race and cancer incidence. When adjusting for ADI, race-associated relative risks increased for TN breast and prostate cancers, with ADI accounting for a statistically significant 2.3% increase in the relationship between race and prostate cancer risk (95% CI 1.1–3.8%, $p < 0.0001$). In contrast, race-associated relative risks decreased for HR+/HER2– breast, colorectal, and lung cancers when adjusting for ADI. ADI attenuated the effect of race by 8.5% (95% CI 4.1–16.6%, $p < 0.0001$) for HR+/HER2– breast cancer incidence and 7.3% (95% CI 3.7–12.8%, $p < 0.0001$) for colorectal cancer incidence. ADI did not significantly attenuate the relationship between race and lung cancer incidence (proportion attenuated: –117%, 95% CI –153–131%, $p = 0.31$).

In a post hoc analysis, we also evaluated interactions between ADI and race. Statistically significant interactions between race and ADI were observed for lung (interaction RR = 1.22, $p < 0.0001$) and prostate (interaction RR = 1.09, $p = 0.00092$) cancer (Figure 2). For lung cancer, the strength of the association between race and incidence increased as ADI quartile increased (Q1: RR = 1.39, 95% CI 1.20–1.61; Q2: RR = 1.68, 95% CI 1.52–1.84; Q3: RR = 1.66, 95% CI 1.49–1.85; Q4: RR = 1.89, 95% CI 1.71–2.08). Interestingly, NHB men were less likely to be diagnosed with prostate cancer compared to NHW men if they lived in regions with lower deprivation (Q1: RR = 0.56, 95% CI 0.43–0.74; Q2: RR = 0.90, 95% CI 0.79–1.01; Q3: RR = 0.76, 95% CI 0.67–0.85), but were more likely to be diagnosed with prostate cancer if they lived in regions with the highest deprivation levels (Q4: RR = 1.27, 95% CI 1.14–1.41).

4 | DISCUSSION

The social construct of race in the United States was developed as a justification for the dependence of the early American economic system on forced labor, particularly the enslavement of Africans and people of African descent.²⁹ Centuries of pervasive systemic and institutional racism have resulted in racially segregated neighborhoods with substantial differences in neighborhood quality and resources, with clear effects on human health including cancer.³⁰ Metropolitan Detroit remains one of the most racially segregated regions in the country,³¹ and it is in this context that we hypothesized not only that neighborhood-level social disadvantage would be associated with cancer incidence, but that it would capture many of the adverse conditions that lead to increased cancer incidence among NHBs compared to NHWs. Indeed, we found that ADI differentially affected cancer risk by race to varying degrees across cancer sites and that ADI attenuated the relationship between race and both HR+/HER2– breast cancer and colorectal cancer incidence. Further, we found that associations between race and both lung and prostate cancer incidence varied by ADI. To understand these associations, it is important to recognize the many ways in which segregation and structural racism have resulted in disproportionate exposure to adverse conditions that affect the health of disadvantaged, and largely NHB, neighborhood residents. These include neighborhood-level characteristics such as pollution and lack of health-promoting resources that directly influence health, as well as the indirect effects of neighborhood through




FIGURE 2 Risk ratios and 95% confidence intervals for the associations between race and cancer incidence are shown for lung and prostate cancer separately by ADI quartile. Height of bars corresponds to the magnitude of the risk ratio. 95% Confidence intervals are depicted by vertical black lines capped with horizontal dashes.

individual-level health behaviors and socioeconomic resources.

Location-based mortgage lending bias (i.e., “redlining”), in which mortgage lenders flagged communities with large NHB populations as hazardous for investment, resulted in segregation of NHBs into neighborhoods with many characteristics that have been shown to chronically impair health. Neighborhood segregation is associated with higher air pollution levels and exposure to fine particulate matter (PM_{2.5}),^{32,33} due to intentional routing of highways and disproportionate placement of landfills, incinerators, airports, and bus depots in NHB and other minority neighborhoods.^{30,34} PM_{2.5} has been associated with increased risk of lung, breast, and colon cancers, independent of cigarette smoking,^{35–37} while nitrogen dioxide and other measures of traffic exposure have been associated with increased lung, breast, and prostate cancer risk.^{38–40} Further, it has been suggested that residents of disadvantaged neighborhoods have increased susceptibility to the adverse health effects of air pollution due to poorer baseline health status and lack of resources to deal with pollution.⁴¹

Neighborhood deprivation further affects health through a lack of access to high quality healthcare and sufficient resources to promote health.^{42,43} We observed that higher ADI was associated with lower rates of breast and prostate cancer, which is likely to be partially reflecting differences in access to cancer screening services such as mammography, digital rectal exams, and prostate-specific antigen testing. Women of higher SES are more likely to report physician recommendations and uptake of mammography,⁴⁴ although some studies have suggested that white women experience more pronounced increases in the likelihood of being screened associated with SES than NHB women.⁴⁵ This is consistent with our observation that the magnitude of the ADI association with breast cancer incidence was stronger for NHW than NHB women. Similarly, residents of socioeconomically disadvantaged neighborhoods are less likely to undergo prostate and colorectal cancer screening.^{46–49} Triple negative breast cancer incidence has also been linked to area-level density of obstetrician/gynecologists.⁵⁰ Further compounding the effects of the lack of high-quality healthcare, smoking-related inequities in disadvantaged neighborhoods are exacerbated by increased availability of cheaper cigarettes and lack of access to effective smoking cessation programs.^{51–54}

Deprived neighborhoods also affect behavioral cancer risk factors such as physical activity, diet, and obesity through lack of access to supermarkets and safe spaces for recreation/physical activity, which is consistent with our observation that higher ADI was associated with higher rates of colorectal and lung cancer.^{17,18} The relationship

between neighborhood and healthy food consumption is complex, and has been found to be a product of diversity in food choices, relative availability of supermarkets versus convenience stores, and changes in neighborhood attributes over time.^{54–57} The built environment seems to have a stronger relationship with physical activity and sedentary behavior, with variability depending on age and gender.^{56,58,59} Importantly, research on neighborhood deprivation and health behaviors such as physical activity and increased fruit/vegetable consumption suggests that interventions and policies that improve environments and reduce deprivation have substantial potential to improve these health behaviors.⁶⁰

Our observed variation in the effect of ADI on racial differences in cancer incidence may partially reflect that there are racial differences in individuals' experiences of area-level socioeconomic deprivation. A recent “neighborhood wide association study” found substantial differences between Black and White men in the roles of housing, education, employment, transportation, and income on the diagnosis of advanced prostate cancer.⁶¹ These differences are further driven by factors such as increased discrimination, social isolation, crime, and limited perceived safety at the neighborhood level.^{62–66} These factors have been associated with increased levels of chronic stress and systemic inflammation.^{67–69} Chronic stress hormones, resulting from perturbation of the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system, promote tumorigenesis through multiple mechanisms.⁷⁰ Chronic stress is also associated with changes in immune function and inflammatory response, which is significant because chronic inflammation and immunosenescence also have demonstrated roles in tumorigenesis.^{70–72}

There were several strengths of our study. First, this was a large analysis using data from the population-based MDCSS registry, increasing both the generalizability and validity of our results. Second, metropolitan Detroit is a racially diverse region, allowing us to have sufficient sample sizes for both NHW and NHB residents to calculate robust measures of incidence and relative risk. Third, we utilized a validated factor-based index of area-level deprivation capturing census indicators of poverty, education, housing, and employment. One limitation of the study is that our analyses were limited to relatively large geographical regions due to the nature of publicly available population count data, which also required that we indirectly calculate ADI for these regions using weighted medians of census-tract level data. Second, we restricted our analyses to include only NHW and NHB residents because other racial/ethnic groups are far less prevalent in metropolitan Detroit, particularly when stratifying by PUMA region. Third, we were unable to obtain length of residence

at current address as well as residential addresses prior to cancer diagnosis, which could be relevant when considering ADI as an etiologic factor. Neighborhood socioeconomic deprivation is likely to play a role throughout the years- or decades-long process of tumorigenesis. These associations may be weakened or undetectable only using residential ADI at the time of cancer diagnosis. Finally, we had limited individual-level data due to the nature of the study design, allowing us to control for sex and age and unable to account for individual SES factors, insurance coverage, and health behaviors, which may in fact partially mediate the association between ADI and cancer incidence. Future studies explicitly designed to evaluate the direct effects of ADI as well as its indirect effects through individual-level behavioral and socioeconomic factors are needed to better understand the mechanisms through which ADI influences cancer incidence.

In summary, area-level socioeconomic disadvantage is associated with risk of common cancers in a racially diverse population, and it plays a role in racial differences in cancer incidence. This highlights the importance of evaluating neighborhood context in understanding cancer risk and racial disparities in cancer, especially when considering etiologic factors that are associated with race and tumor aggressiveness. Future work to obtain information at the individual- and area-levels will provide valuable insight on how best to focus efforts at cancer prevention and reduction of racial disparities in cancer risk. Most cancer prevention efforts to date, including those designed to reduce health disparities, have focused on changing behavior at the individual, interpersonal, or community levels; however, these have not translated to sustainable, long-term reductions in racial cancer disparities in part because they do not address the structural barriers that prevent meaningful behavior change, such as lack of access to high quality healthcare, recreational spaces for physical activity, and low-cost healthy food options.^{73,74} A better understanding of the mechanisms—both direct and indirect—by which area-level socioeconomic disadvantage affects cancer incidence would help inform scientific and policy-level discussions about the benefit of upstream structural interventions to make meaningful improvements in racial health equity.

AUTHOR CONTRIBUTIONS

Kristen S. Purrington: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead); writing – review and editing (lead). **Theresa A. Hastert:** Conceptualization (supporting); methodology (supporting); writing – review and editing (equal). **KC Madhav:** Data curation (supporting); formal analysis (supporting); writing – review and editing (equal). **Mrudula Nair:** Data curation (supporting); writing – review and editing (equal). **Natalie Snider:**

Conceptualization (supporting); formal analysis (supporting); writing – review and editing (equal). **Julie J. Ruterbusch:** Data curation (equal); formal analysis (supporting); writing – review and editing (equal). **Ann G. Schwartz:** Data curation (supporting); writing – review and editing (equal). **Elena M. Stoffel:** Conceptualization (supporting); writing – review and editing (equal). **Edward S. Peters:** Conceptualization (supporting); data curation (supporting); writing – review and editing (equal). **Laura S. Rozek:** Conceptualization (equal); data curation (supporting); writing – review and editing (supporting).

ACKNOWLEDGMENTS

None.

FUNDING INFORMATION

This work was supported, in part, by NCI R01CA259420, and the Epidemiology Research Core and NIH Center Grant P30CA022453 to the Karmanos Cancer Institute at Wayne State University for conduct of the study. This work was also supported in part by contract HHSN261201300011I.


CONFLICT OF INTEREST STATEMENT

The authors have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

The United States census data that support the findings of this study are available at <https://usa.ipums.org/usa/> (Sample 201,603), <https://gis-michigan.opendata.arcgis.com/datasets/> (2010 Census Tracts v17a), and <https://data.census.gov/mdat/#/> (Dataset: ACS 5-Year Estimates 5-Year Estimates – Public Use Microdata Sample; Vintage: 2013). Metropolitan Detroit cancer data are available by request from the Metropolitan Detroit Cancer Surveillance System with appropriate Institutional Review Board approvals.

ORCID

Kristen S. Purrington  <https://orcid.org/0000-0002-5710-1692>

Theresa A. Hastert  <https://orcid.org/0000-0001-6251-6422>

REFERENCES

1. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *J Natl Cancer Inst.* 2015;107(6):djv048. doi:10.1093/jnci/djv048
2. Ozdemir BC, Dotto GP. Racial differences in cancer susceptibility and survival: more than the color of the skin? *Trends Cancer.* 2017;3(3):181-197. doi:10.1016/j.trecan.2017.02.002
3. Esnaola NF, Ford ME. Racial differences and disparities in cancer care and outcomes: where's the rub? *Surg Oncol Clin N Am.* 2012;21(3):417-437, viii. doi:10.1016/j.soc.2012.03.012

4. Zavala VA, Bracci PM, Carethers JM, et al. Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer*. 2021;124(2):315-332. doi:10.1038/s41416-020-01038-6
5. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and White patients with Covid-19. *N Engl J Med*. 2020;382:2534-2543. doi:10.1056/NEJMsa2011686
6. Jackson RJ. The impact of the built environment on health: an emerging field. *Am J Public Health*. 2003;93(9):1382-1384. doi:10.2105/ajph.93.9.1382
7. Gomez SL, Shariff-Marco S, DeRouen M, et al. The impact of neighborhood social and built environment factors across the cancer continuum: current research, methodological considerations, and future directions. *Cancer*. 2015;121(14):2314-2330. doi:10.1002/cncr.29345
8. Krieger N, Singh N, Waterman PD. Metrics for monitoring cancer inequities: residential segregation, the index of concentration at the extremes (ICE), and breast cancer estrogen receptor status (USA, 1992-2012). *Cancer Causes Control*. 2016;27(9):1139-1151. doi:10.1007/s10552-016-0793-7
9. Krieger N, Jahn JL, Waterman PD. Jim crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. *Cancer Causes Control*. 2017;28(1):49-59. doi:10.1007/s10552-016-0834-2
10. Krieger N, Wright E, Chen JT, Waterman PD, Huntley ER, Arcaya M. Cancer stage at diagnosis, historical redlining, and current neighborhood characteristics: breast, cervical, lung, and colorectal cancers, Massachusetts, 2001-2015. *Am J Epidemiol*. 2020;189(10):1065-1075. doi:10.1093/aje/kwaa045
11. Polite BN, Adams-Campbell LL, Brawley OW, et al. Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. *CA Cancer J Clin*. 2017;67(5):353-361. doi:10.3322/caac.21404
12. Shariff-Marco S, Yang J, John EM, et al. Intersection of race/ethnicity and socioeconomic status in mortality after breast cancer. *J Community Health*. 2015;40(6):1287-1299. doi:10.1007/s10900-015-0052-y
13. Warren Andersen S, Blot WJ, Lipworth L, Steinwandel M, Murff HJ, Zheng W. Association of Race and Socioeconomic Status with Colorectal Cancer Screening, colorectal cancer risk, and mortality in southern US adults. *JAMA Netw Open*. 2019;2(12):e1917995. doi:10.1001/jamanetworkopen.2019.17995
14. Karanth S, Fowler ME, Mao X, et al. Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis. *JNCI Cancer Spectr*. 2019;3(4):pkz084. doi:10.1093/jncics/pkz084
15. Akinyemiju TF, Pisu M, Waterbor JW, Altekruse SF. Socioeconomic status and incidence of breast cancer by hormone receptor subtype. *Springerplus*. 2015;4:508. doi:10.1186/s40064-015-1282-2
16. Rundle A, Neckerman KM, Sheehan D, et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. *Cancer Causes Control*. 2013;24(2):297-303. doi:10.1007/s10552-012-0108-6
17. Steinbrecher A, Fish K, Clarke CA, West DW, Gomez SL, Cheng I. Examining the association between socioeconomic status and invasive colorectal cancer incidence and mortality in California. *Cancer Epidemiol Biomarkers Prev*. 2012;21(10):1814-1822. doi:10.1158/1055-9965.EPI-12-0659
18. Hovanec J, Siemiatycki J, Conway DI, et al. Lung cancer and socioeconomic status in a pooled analysis of case-control studies. *PLoS One*. 2018;13(2):e0192999. doi:10.1371/journal.pone.0192999
19. Silver E, Mulvey EP, Swanson JW. Neighborhood structural characteristics and mental disorder: Faris and Dunham revisited. *Soc Sci Med*. 2002;55(8):1457-1470. doi:10.1016/S0277-9536(01)00266-0
20. Bassett E, Moore S. Gender differences in the social pathways linking neighborhood disadvantage to depressive symptoms in adults. *PLoS One*. 2013;8(10):e76554. doi:10.1371/journal.pone.0076554
21. Hastert TA, Beresford SA, Sheppard L, White E. Disparities in cancer incidence and mortality by area-level socioeconomic status: a multilevel analysis. *J Epidemiol Community Health*. 2015;69(2):168-176. doi:10.1136/jech-2014-204417
22. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. *J Clin Oncol*. 2018;36(1):25-33. doi:10.1200/JCO.2017.74.2049
23. Kwak M, Kim C. Effect of area-level deprivation on cancer survival time: a register-based follow-up study of 145 585 Korean subjects. *Asia Pac J Public Health*. 2018;30(1):19-28. doi:10.1177/1010539517746043
24. Adie Y, Kats DJ, Tlimat A, et al. Neighborhood disadvantage and lung cancer incidence in ever-smokers at a safety net health-care system: a retrospective study. *Chest*. 2020;157(4):1021-1029. doi:10.1016/j.chest.2019.11.033
25. Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible - the neighborhood atlas. *N Engl J Med*. 2018;378(26):2456-2458. doi:10.1056/NEJMp1802313
26. Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. *Ann Intern Med*. 2014;161(11):765-774. doi:10.7326/M13-2946
27. Singh GK. Area deprivation and widening inequalities in US mortality, 1969-1998. *Am J Public Health*. 2003;93(7):1137-1143. doi:10.2105/ajph.93.7.1137
28. Anselin L, Syabri I, Kho Y. GeoDa: an introduction to spatial data analysis. *Geogr Anal*. 2006;38(1):5-22.
29. Culture NMoAAH. Historical foundations of race. *Smithsonian Institution*. Accessed April 28, 2022. <https://nmaahc.si.edu/learn/talking-about-race/topics/historical-foundations-race>
30. Ashing KT, Jones V, Bedell F, Phillips T, Erhunmwunsee L. Calling attention to the role of race-driven societal determinants of health on aggressive tumor biology: a focus on black Americans. *JCO Oncol Pract*. 2022;18(1):15-22. doi:10.1200/OP.21.00297
31. Institute OB. Most to Least Segregated Metro Regions. Accessed April 15, 2022. <https://belonging.berkeley.edu/most-least-segregated-metro-region>
32. Namin S, Xu W, Zhou Y, Beyer K. The legacy of the Home Owners' Loan Corporation and the political ecology of urban trees and air pollution in the United States. *Soc Sci Med*. 2020;246:112758. doi:10.1016/j.socscimed.2019.112758
33. Tessum CW, Apte JS, Goodkind AL, et al. Inequity in consumption of goods and services adds to racial-ethnic disparities in air

- pollution exposure. *Proc Natl Acad Sci U S A*. 2019;116(13):6001-6006. doi:10.1073/pnas.1818859116
34. Hajat A, Hsia C, O'Neill MS. Socioeconomic disparities and air pollution exposure: a global review. *Curr Environ Health Rep*. 2015;2(4):440-450. doi:10.1007/s40572-015-0069-5
 35. Prada D, Baccarelli AA, Terry MB, et al. Long-term PM_{2.5} exposure before diagnosis is associated with worse outcome in breast cancer. *Breast Cancer Res Treat*. 2021;188(2):525-533. doi:10.1007/s10549-021-06167-x
 36. Ciabattini M, Rizzello E, Lucaroni F, Palombi L, Boffetta P. Systematic review and meta-analysis of recent high-quality studies on exposure to particulate matter and risk of lung cancer. *Environ Res*. 2021;196:110440. doi:10.1016/j.envres.2020.110440
 37. Coleman NC, Burnett RT, Higbee JD, et al. Cancer mortality risk, fine particulate air pollution, and smoking in a large, representative cohort of US adults. *Cancer Causes Control*. 2020;31(8):767-776. doi:10.1007/s10552-020-01317-w
 38. Hamra GB, Laden F, Cohen AJ, Raaschou-Nielsen O, Brauer M, Loomis D. Lung cancer and exposure to nitrogen dioxide and traffic: a systematic review and meta-analysis. *Environ Health Perspect*. 2015;123(11):1107-1112. doi:10.1289/ehp.1408882
 39. White AJ, Keller JP, Zhao S, Carroll R, Kaufman JD, Sandler DP. Air pollution, clustering of particulate matter components, and breast cancer in the sister study: a U.S.-wide cohort. *Environ Health Perspect*. 2019;127(10):107002. doi:10.1289/EHP5131
 40. Parent ME, Goldberg MS, Crouse DL, et al. Traffic-related air pollution and prostate cancer risk: a case-control study in Montreal, Canada. *Occup Environ Med*. 2013;70(7):511-518. doi:10.1136/oemed-2012-101211
 41. Hooper LG, Kaufman JD. Ambient air pollution and clinical implications for susceptible populations. *Ann Am Thorac Soc*. 2018;15(Suppl 2):S64-S68. doi:10.1513/AnnalsATS.201707-574MG
 42. Williams DR, Jackson PB. Social sources of racial disparities in health. *Health Aff (Millwood)*. 2005;24(2):325-334. doi:10.1377/hlthaff.24.2.325
 43. Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. *Med Care*. 2005;43(2):141-148. doi:10.1097/00005650-200502000-00007
 44. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). *Cancer Epidemiol Biomarkers Prev*. 2009;18(1):121-131. doi:10.1158/1055-9965.EPI-08-0679
 45. Monnat SM. Race/ethnicity and the socioeconomic status gradient in women's cancer screening utilization: a case of diminishing returns? *J Health Care Poor Underserved*. 2014;25(1):332-356. doi:10.1353/hpu.2014.0050
 46. Wu CC, Lin CH, Chiang HS, Tang MJ. A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan. *Int J Equity Health*. 2018;17(1):79. doi:10.1186/s12939-018-0792-2
 47. Kilpelainen TP, Talala K, Raitanen J, et al. Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer. *Am J Epidemiol*. 2016;184(10):720-731. doi:10.1093/aje/kww084
 48. Reynolds D. Prostate cancer screening in African American men: barriers and methods for improvement. *Am J Mens Health*. 2008;2(2):172-177. doi:10.1177/1557988307312784
 49. Vutien P, Shah R, Ma K, Saleem N, Melson J. Utilization of census tract-based neighborhood poverty rates to predict non-adherence to screening colonoscopy. *Dig Dis Sci*. 2019;64(9):2505-2513. doi:10.1007/s10620-019-05585-8
 50. Moss JL, Tatalovich Z, Zhu L, Morgan C, Cronin KA. Triple-negative breast cancer incidence in the United States: ecological correlations with area-level sociodemographics, healthcare, and health behaviors. *Breast Cancer*. 2021;28(1):82-91. doi:10.1007/s12282-020-01132-w
 51. Raskind IG, Vishwakarma M, Schleicher NC, Andersen-Rodgers E, Henriksen L. The changing retail landscape for tobacco: dollar stores and the availability of cheap cigarettes among tobacco-related priority populations. *Tob Control*. 2021;31:e140-e147. doi:10.1136/tobaccocontrol-2020-056389
 52. Henriksen L, Andersen-Rodgers E, Zhang X, et al. Neighborhood variation in the Price of cheap tobacco products in California: results from healthy Stores for a Healthy Community. *Nicotine Tob Res*. 2017;19(11):1330-1337. doi:10.1093/ntr/ntx089
 53. Mills SD, Golden SD, Henriksen L, Kong AY, Queen TL, Ribisl KM. Neighbourhood disparities in the price of the cheapest cigarettes in the USA. *J Epidemiol Community Health*. 2019;73(9):894-896. doi:10.1136/jech-2018-210998
 54. Wallace LA, Paul R, Gholizadeh S, et al. Neighborhood disadvantage and the sales of unhealthy products: alcohol, tobacco and unhealthy snack food. *BMC Public Health*. 2021;21(1):1361. doi:10.1186/s12889-021-11442-z
 55. Peng K, Kaza N. Availability of neighbourhood supermarkets and convenience stores, broader built environment context, and the purchase of fruits and vegetables in US households. *Public Health Nutr*. 2019;22(13):2436-2447. doi:10.1017/S136898001900910
 56. Alves L, Silva S, Severo M, et al. Association between neighborhood deprivation and fruits and vegetables consumption and leisure-time physical activity: a cross-sectional multilevel analysis. *BMC Public Health*. 2013;13:1103. doi:10.1186/1471-2458-13-1103
 57. Shvetsov YB, Shariff-Marco S, Yang J, et al. Association of change in the neighborhood obesogenic environment with colorectal cancer risk: the multiethnic cohort study. *SSM Popul Health*. 2020;10:100532. doi:10.1016/j.ssmph.2019.100532
 58. Drewnowski A, Aggarwal A, Tang W, et al. Obesity, diet quality, physical activity, and the built environment: the need for behavioral pathways. *BMC Public Health*. 2016;16(1):1153. doi:10.1186/s12889-016-3798-y
 59. Xiao Q, Keadle SK, Berrigan D, Matthews CE. A prospective investigation of neighborhood socioeconomic deprivation and physical activity and sedentary behavior in older adults. *Prev Med*. 2018;111:14-20. doi:10.1016/j.ypmed.2018.02.011
 60. Moss JL, Xiao Q, Matthews CE. Patterns of cancer-related health behaviors among middle-aged and older adults: individual- and area-level socioeconomic disparities. *Prev Med*. 2018;115:31-38. doi:10.1016/j.ypmed.2018.08.003
 61. Lynch SM, Sorice K, Tagai EK, Handorf EA. Use of empiric methods to inform prostate cancer health disparities: comparison of neighborhood-wide association study "hits" in black and white men. *Cancer*. 2020;126(9):1949-1957. doi:10.1002/cncr.32734
 62. Landrine H, Corral I, Lee JGL, Eford JT, Hall MB, Bess JJ. Residential segregation and racial cancer disparities: a systematic review. *J Racial Ethn Health Disparities*. 2017;4(6):1195-1205. doi:10.1007/s40615-016-0326-9

63. Ferdows NB, Aranda MP, Baldwin JA, Baghban Ferdows S, Ahluwalia JS, Kumar A. Assessment of racial disparities in mortality rates among older adults living in US rural vs urban counties from 1968 to 2016. *JAMA Netw Open*. 2020;3(8):e2012241. doi:10.1001/jamanetworkopen.2020.12241
64. Pruitt SL, Lee SJ, Tiro JA, Xuan L, Ruiz JM, Inrig S. Residential racial segregation and mortality among black, white, and Hispanic urban breast cancer patients in Texas, 1995 to 2009. *Cancer*. 2015;121(11):1845-1855. doi:10.1002/cncr.29282
65. Williams DR. Race, socioeconomic status, and health. The added effects of racism and discrimination. *Ann N Y Acad Sci*. 1999;896:173-188. doi:10.1111/j.1749-6632.1999.tb08114.x
66. Ribeiro AI, Amaro J, Lisi C, Fraga S. Neighborhood socioeconomic deprivation and allostatic load: a scoping review. *Int J Environ Res Public Health*. 2018;15(6):1092. doi:10.3390/ijerph15061092
67. Simons RL, Lei MK, Beach SRH, et al. Discrimination, segregation, and chronic inflammation: testing the weathering explanation for the poor health of black Americans. *Dev Psychol*. 2018;54(10):1993-2006. doi:10.1037/dev0000511
68. Thames AD, Irwin MR, Breen EC, Cole SW. Experienced discrimination and racial differences in leukocyte gene expression. *Psychoneuroendocrinology*. 2019;106:277-283. doi:10.1016/j.psyneuen.2019.04.016
69. Berger M, Sarnyai Z. "More than skin deep": stress neurobiology and mental health consequences of racial discrimination. *Stress*. 2015;18(1):1-10. doi:10.3109/10253890.2014.989204
70. Dai S, Mo Y, Wang Y, et al. Chronic stress promotes cancer development. *Front Oncol*. 2020;10:1492. doi:10.3389/fonc.2020.01492
71. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860-867. doi:10.1038/nature01322
72. Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. *J Hematol Oncol*. 2020;13(1):151. doi:10.1186/s13045-020-00986-z
73. Brown AF, Ma GX, Miranda J, et al. Structural interventions to reduce and eliminate health disparities. *Am J Public Health*. 2019;109(S1):S72-S78. doi:10.2105/AJPH.2018.304844
74. Clark EC, Cranston E, Polin T, et al. Structural interventions that affect racial inequities and their impact on population health outcomes: a systematic review. *BMC Public Health*. 2022;22(1):2162. doi:10.1186/s12889-022-14603-w

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Purrington KS, Hastert TA, Madhav KC, et al. The role of area-level socioeconomic disadvantage in racial disparities in cancer incidence in metropolitan Detroit. *Cancer Med*. 2023;12:14623-14635. doi:10.1002/cam4.6065